HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.

Abstract
The incidence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has increased in parallel with the incidence of obesity. While both NAFLD and NASH are characterized by hepatosteatosis, NASH is characterized by hepatic damage, inflammation, oxidative stress, and fibrosis. We previously reported that feeding Ldlr(-/-) mice a high-fat, high-cholesterol diet containing menhaden oil attenuated several markers of NASH, including hepatosteatosis, inflammation, and fibrosis. Herein, we test the hypothesis that DHA [22:6 (n-3)] is more effective than EPA [20:5 (n-3)] at preventing Western diet (WD)-induced NASH in Ldlr(-/-) mice. Mice were fed the WD supplemented with either olive oil (OO), EPA, DHA, or EPA + DHA for 16 wk. WD + OO feeding induced a severe NASH phenotype, characterized by robust hepatosteatosis, inflammation, oxidative stress, and fibrosis. Whereas none of the C20-22 (n-3) fatty acid treatments prevented WD-induced hepatosteatosis, all 3 (n-3) PUFA-containing diets significantly attenuated WD-induced inflammation, fibrosis, and hepatic damage. The capacity of dietary DHA to suppress hepatic markers of inflammation (Clec4F, F4/80, Trl4, Trl9, CD14, Myd88), fibrosis (Procol1α1, Tgfβ1), and oxidative stress (NADPH oxidase subunits Nox2, p22phox, p40phox, p47phox, p67phox) was significantly greater than dietary EPA. The effects of DHA on these markers paralleled DHA-mediated suppression of hepatic Fads1 mRNA abundance and hepatic arachidonic acid content. Because DHA suppression of NASH markers does not require a reduction in hepatosteatosis, dietary DHA may be useful in combating NASH in obese humans.
AuthorsChristopher M Depner, Kenneth A Philbrick, Donald B Jump
JournalThe Journal of nutrition (J Nutr) Vol. 143 Issue 3 Pg. 315-23 (Mar 2013) ISSN: 1541-6100 [Electronic] United States
PMID23303872 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Biomarkers
  • Delta-5 Fatty Acid Desaturase
  • Dietary Fats
  • Inflammation Mediators
  • RNA, Messenger
  • Receptors, LDL
  • Docosahexaenoic Acids
  • Arachidonic Acid
  • Eicosapentaenoic Acid
  • Fatty Acid Desaturases
  • FADS1 protein, human
Topics
  • Animals
  • Arachidonic Acid (metabolism)
  • Biomarkers (metabolism)
  • Delta-5 Fatty Acid Desaturase
  • Diet (adverse effects)
  • Dietary Fats (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Docosahexaenoic Acids (metabolism, pharmacology, therapeutic use)
  • Eicosapentaenoic Acid (metabolism, pharmacology)
  • Fatty Acid Desaturases (genetics, metabolism)
  • Fatty Liver (drug therapy, genetics, metabolism, pathology)
  • Fibrosis (etiology, metabolism, prevention & control)
  • Inflammation (etiology, metabolism, prevention & control)
  • Inflammation Mediators (metabolism)
  • Liver (drug effects, metabolism, pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Oxidative Stress (drug effects)
  • RNA, Messenger (metabolism)
  • Receptors, LDL (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: